

PROUDLY HOSTED BY



World class cancer care. Close to home.

4th Annual BREAST CANCER SYMPOSIUM

OPENING DOORS: Lab to Clinic to Patient

September 23-25, 2022

Hudson Hall Opera House
Hudson, NY

This activity has been approved for

16.5 *AMA PRA
Category 1 Credits™*

ACCREDITED PROVIDER



AT THE FOREFRONT
**UChicago
Medicine**

ACTIVITY PLANNED BY



myMedEd

4th Annual BREAST CANCER SYMPOSIUM

OPENING DOORS: Lab to Clinic to Patient

PRESENTATION DOWNLOAD

The accredited content presented during the conference will be posted online for viewing and download within 30 days after the conference. An email will be sent to all participants with viewing and download instructions. Not all presentations will be shared due to reprint and permission restrictions.



HOW TO CLAIM CREDIT

In Person Attendance

Sign in each day at the registration desk.

Virtual Attendance

Log in each day on the conference platform.

You will be emailed instructions for completing the post-test, program evaluation, claiming credit and printing your certificate within 7 days following the conference.



FOR QUESTIONS OR TECHNICAL ASSISTANCE

Email BCS@mymededco.com

bcsny2022.com

Dear Breast Cancer Symposium Attendees:

It is my pleasure to welcome you to New York Oncology Hematology's 4th Annual Breast Cancer Symposium. We are so excited by the tremendous growth and prominence of this event. Of course, we also look forward to the time when we can come together in person and celebrate the remarkable advances in breast cancer care. Those days are right around the corner!

This conference expresses the passion and compassion of our conference Course Chair and Moderator, Dr. Maria Theodoulou, for the holistic care of women with breast cancer. Ever grounded in science, with rapidly evolving data of translational research trials, and delivered by an esteemed faculty in the breast cancer world.

We thank our event sponsors for their support to bring this conference to you.

Thank you so much for attending and enjoy this engaging time together!

Sincerely,



Todd Doyle, MD

President, New York Oncology Hematology

**PLEASE BE SURE TO VISIT OUR
SPONSORS AND EXHIBITORS ON THE 1ST FLOOR**

If participating online, please visit the exhibit hall.

Dear Friends and Colleagues,

First, I want to thank everyone on behalf of New York Oncology Hematology for supporting the 4th Annual Breast Cancer Symposium, Opening Doors: Lab to Clinic to Patient, a CME educational program. I am grateful to the faculty presenting the results of cutting-edge research that guides our treatment of patients with breast cancer. I am grateful to the attendees who want to take this information back to their clinical practices, confirming the excellence of care that they are already performing, or adding to that excellence of care. I am grateful for all the grant support received for this symposium which has allowed us to offer this program free of charge.

This year our program is live and virtual finally allowing us to come together in a live setting, interacting, sharing information, and building on the hope of tomorrow and for future educational symposiums.

The dedication of scientists, clinicians and all of the ancillary and supportive services in the oncologic community have continued to move forward with the goal of success and cure in the breast cancer arena.

This year most of our faculty enthusiastically agreed to come live. The agenda is comprised of nationally and internationally known speakers. We will hear about updates that have impacted the clinical pathways available for patients diagnosed with breast cancer in the early setting as well as the advanced setting, novel ways of dissecting an individual patient's breast cancer diagnosis and risk and how to optimize the patient's survival outcomes. Late breaking data from ESMO one week ago will be presented.

Clearly COVID has not impeded or delayed the research and science that has allowed us to continue to develop new standards of care, continuing to move forward with research from bench to clinic. For three days we will have conversations that will educate and excite us all for when we meet our patients again in our respective clinics the following Monday.

Thank you for being part of this educational event. We are all excited on the podium side and I hope you are all excited as attendees.

Most importantly, I want to thank our patients for trusting us on a daily basis to bring them the newest standards of care for treatment and support. They allow us into their intimate private world, they motivate us to be the best that we can be.

Sincerely,

A handwritten signature in black ink, reading "Maria Theodoulou". The signature is fluid and cursive, with the first name "Maria" and last name "Theodoulou" clearly distinguishable.

Maria Theodoulou, MD, Program Chair
Program Director Breast Cancer Medicine
New York Oncology Hematology

4th Annual BREAST CANCER SYMPOSIUM

OPENING DOORS: Lab to Clinic to Patient

The Conference is being held in Eastern Daylight Time



FRIDAY, SEPTEMBER 23, 2022

8:00 AM - 9:30 AM REGISTRATION, EXHIBITS, OPTIONAL ANCILLARY EVENTS

8:45 AM - 9:30 AM OPTIONAL ANCILLARY EVENT — WEST ROOM, 1ST FLOOR

9:45 AM - 10:00 AM INTRODUCTION / OPENING

—Dr. Maria Theodoulou (NYOH)

10:00 AM - 11:00 AM Breast Imaging

—Dr. Elizabeth Morris (UC Davis)

PATHOLOGY SESSION | Moderators: Dr. Maria Theodoulou (NYOH) and Dr. Anna Boguniewicz (AMC)

11:00 AM - 12:00 PM Pathology

—Dr. Edi Brogi (MSKCC)

12:00 PM - 1:00 PM BREAK, EXHIBITS, OPTIONAL ANCILLARY EVENTS

12:00 PM - 1:00 PM OPTIONAL ANCILLARY EVENT — WEST ROOM, 1ST FLOOR

BREAST SURGERY SESSION | Moderator: Dr. Rakel Astorga (AMC)

1:00 PM - 1:30 PM Management of the Breast and Axilla
—Who Needs Upfront Surgery?

—Dr. Hiram Cody (MSKCC)

1:30 PM - 2:00 PM Management of the Breast and Axilla in Patients Who
Receive Neoadjuvant Therapy

—Dr. Eleftherios Mamounas (OHCI)

2:00 PM - 2:30 PM Reconstruction Post NAC and RT

—Dr. Babak Mehrara (MSKCC)

2:30 PM - 2:45 PM DISCUSSION

2:45 PM - 3:15 PM Genetics Related to Breast and Ovarian Cancer

—Dr. Elizabeth Poynor (NYU)

3:15 PM - 3:30 PM BREAK

RADIATION THERAPY SESSION | Moderator: Dr. Tia Olds (NYOH)

3:30 PM - 4:00 PM Updates in Who Should Receive and Who Can Avoid
Adjuvant Breast Radiation

—Dr. Yasmin Hasan (UOC)

4:00 PM - 4:30 PM Breast Radiation Update: Short Course RT —
Benefits of Downsides and DCIS: Does everyone need
RT after conservation surgery?

—Dr. Beryl McCormick (MSKCC)

4:30 PM - 4:45 PM DISCUSSION

4:45 PM - 4:50 PM DAY 1 – CLOSING

—Dr. Maria Theodoulou (NYOH)

SATURDAY, SEPTEMBER 24, 2022

8:00 AM - 9:30 AM REGISTRATION, EXHIBITS, OPTIONAL ANCILLARY EVENTS

8:00 AM - 8:45 AM OPTIONAL ANCILLARY EVENT — PERFORMANCE HALL, 2ND FLOOR

8:45 AM - 9:30 AM OPTIONAL ANCILLARY EVENT — WEST ROOM, 1ST FLOOR

9:45 AM - 9:50 AM INTRODUCTION / HIGHLIGHTS FROM FRIDAY

—Dr. Maria Theodoulou (NYOH)
and Dr. Rufus Collea (NYOH)

9:50 AM - 10:20 AM Molecular Profiling for Metastatic Breast Cancer Management:
Who, What, When, and Why

—Dr. Andrew Seidman (MSKCC)

10:20 AM - 10:50 AM Optimizing Lifestyle to Improve Cancer Outcomes

—Dr. Neil Iyengar (MSKCC)

10:50 AM - 11:00 AM Q&A

11:00 AM - 11:30 AM KEYNOTE

—Dr. Shanu Modi (MSKCC)

11:30 AM - 12:30 PM BREAK, EXHIBITS, OPTIONAL ANCILLARY EVENTS

4th Annual BREAST CANCER SYMPOSIUM

OPENING DOORS: Lab to Clinic to Patient



SATURDAY, SEPTEMBER 24, 2022

11:30 AM - 12:30 PM	OPTIONAL ANCILLARY EVENT — WEST ROOM, 1ST FLOOR	
12:30 PM - 1:00 PM	Leveraging the Lessons of COVID19	—Dr. Reshma Mahtani (MCI)
1:00 PM - 1:30 PM	Early Stage Triple Negative Breast Cancer	—Dr. Kevin Kalinsky (EMORY)
1:30 PM - 2:00 PM	Updates in the Management of Advanced TNBC	—Dr. Tiffany Traina (MSKCC)
2:00 PM - 2:30 PM	Current and Future Directions	—Dr. Heather McArthur (UT SMC)
2:30 PM - 2:45 PM	DISCUSSION	
2:45 PM - 3:00 PM	BREAK	
3:00 PM - 3:30 PM	New and Emerging Systemic Treatment Options for Breast Cancer Brain Metastases: Beyond Surgery and Radiotherapy	—Dr. Andrew Seidman (MSKCC)
3:30 PM - 4:00 PM	Advances in the Treatment of ER+ Early Stage Breast Cancer	—Dr. Claudine Isaacs (GU)
4:00 PM - 4:30 PM	Updates in the Management of Advanced Hormone Positive, HER2 Negative Breast Cancer	—Dr. Anne O'Dea (KU)
4:30 PM - 4:35 PM	DAY 2 – CLOSING	—Dr. Maria Theodoulou (NYOH) and Dr. Rufus Collea (NYOH)
5:00 PM - 7:00 PM	OPTIONAL ANCILLARY EVENTS	

SUNDAY, SEPTEMBER 25, 2022

8:00 AM - 9:30 AM	REGISTRATION, EXHIBITS, OPTIONAL ANCILLARY EVENTS	
8:00 AM - 8:45 AM	OPTIONAL ANCILLARY EVENT — PERFORMANCE HALL, 2ND FLOOR	
8:45 AM - 9:30 AM	OPTIONAL ANCILLARY EVENT — WEST ROOM, 1ST FLOOR	
9:45 AM - 9:50 AM	INTRODUCTION/HIGHLIGHTS FROM SATURDAY	—Dr. Maria Theodoulou (NYOH) and Dr. Rufus Collea (NYOH)
9:50 AM - 10:20 AM	Bone Density and Bone Health	—Dr. Azeez Farooki (MSKCC)
10:20 AM - 10:50 AM	Bone Density and Breast Cancer	—Dr. Monica Fornier (MSKCC)
10:50 AM - 11:00 AM	Q&A	
11:00 AM - 11:30 AM	End or Ending a Life	—Dr. Monique James (MSKCC)
11:30 AM - 12:00 PM	Arena Award and the Community	—Dr. Francis Arena (NYU)
12:00 PM - 12:30 PM	Arena Advocacy Awardee and Presentation	—Dr. Elizabeth Poynor (NYU)
12:30 PM - 1:30 PM	BREAK, EXHIBITS, OPTIONAL ANCILLARY EVENTS	
12:30 PM - 1:30 PM	HER2 CME SYMPOSIUM — PERFORMANCE HALL, 2ND FLOOR	
1:30 PM - 2:00 PM	HER2neu Early	—Dr. Chau Dang (MSKCC)
2:00 PM - 2:30 PM	EHER2neu Late	—Dr. VK Gadi (UOIC)
2:30 PM - 3:00 PM	Management of HER2-Positive Early Breast Cancer in the Older Patient	—Dr. Hyman Muss (UNC)
3:00 PM - 3:30 PM	DISCUSSION AND Q&A	
3:30 PM - 3:40 PM	SUNDAY SESSION CLOSE	—Dr. Maria Theodoulou (NYOH) and Dr. Rufus Collea (NYOH)

EDUCATIONAL GOAL

Advances in our understanding of the genetic and physiologic pathways of breast cancer have led to the development of targeted systemic therapies, improved surgical procedures, and radiation techniques, and improved, disease-free, and overall survival benefits. The goal of this conference is to educate the medical and global community in a forum that will facilitate the utilization of optimal treatment strategies and foster communication that will benefit the individual patient as well as the community.

TARGET AUDIENCE

Medical, surgical, and radiation oncologists as well as primary care physicians, gynecologists, medical professionals and health care professionals with an interest in breast cancer are invited to attend.

LEARNING OBJECTIVES

After completing this activity, participants will be able to:

- Review the recent developments in breast surgical approaches including upfront and after neoadjuvant chemotherapy
- Explain the rationale for reconstruction options post neoadjuvant chemotherapy and radiation therapy
- Discuss updates in breast cancer imaging for earlier detection
- Identify therapeutic advances in early and advanced hormone receptor-positive, HER2 neu overexpressing, and triple-negative breast cancer
- Review the advances in radiation therapy and outcomes including short-course radiation therapy and de-escalation
- Describe the management of HER2 positive early breast cancer in the older patient
- Review the treatment of early-stage inherited breast cancer
- Identify the new and emerging systemic treatment options for breast cancer brain metastases beyond surgery and radiotherapy
- Describe molecular profiling for metastatic breast cancer management
- Explain the mechanism of action and rationale for immunotherapy

FEE INFORMATION

The fee for this educational activity is \$250 for physicians (MD/DO), \$150 for advanced practice professionals (NP/PA) and \$50 for all other allied health professionals (RNs/Other).

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council of Continuing Medical Education

(ACCME) through the joint providership of The University of Chicago Pritzker School of Medicine, and New York Oncology Hematology, and in collaboration with myMedEd, Inc. The University of Chicago Pritzker School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.



AT THE FOREFRONT

UChicago
Medicine

CREDIT DESIGNATION STATEMENT

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 16.5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses and other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for *AMA PRA Category 1 Credits™* from organizations accredited by the ACCME, please consult your professional licensing board.

DISCLOSURE DECLARATIONS

As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.

Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.

PLANNING COMMITTEE AND MODERATORS

Maria Theodoulou, MD (Course Chair & Moderator)

Program Director
Breast Cancer Medicine
New York Oncology Hematology
Albany, NY

Rakel Astorga, MD

Breast and General Surgery
Albany Med Health System
Chief of Surgery
Columbia Memorial Hospital
Hudson, NY

Anna Boguniewicz, MD

Associate Professor
Director, Pathology Residency
Training Program
Department of Pathology and
Laboratory Medicine
Albany Medical Center
Albany, NY

Rufus Colleale, MD

Breast Oncology
New York Oncology Hematology
Clinical Assistant Professor
Albany Medical Center
Medical Director
New York Oncology Hematology
Albany, NY

Tia Olds, MD

Radiation Oncologist
New York Oncology Hematology
Albany, NY

FACULTY

Francis Arena, MD

Director
NYU Langone Arena Oncology
Clinical Professor
NYU Health Medical College
President and Director of Research
Sass Foundation for Medical Research
Lake Success, NY

Edi Brogi, MD, PhD

Director of Breast Pathology
and Attending Pathologist
Memorial Sloan Kettering
Cancer Center
Professor of Clinical Pathology
and Laboratory Medicine
Weill Cornell Medical College
New York, NY

Hiram S. Cody III, MD

Attending Surgeon, Breast Service
Department of Surgery
Memorial Sloan Kettering
Cancer Center
Professor of Surgery
Weill Cornell Medical College
New York, NY

Chau T. Dang, MD

MSK Westchester Medical Oncology
Attending, Breast Medicine Service
Memorial Sloan Kettering
Cancer Center
New York, NY

Azeez Farooki, MD

Attending Physician
Endocrinology Service
Memorial Sloan Kettering
Cancer Center
New York, NY

Monica Fornier, MD

Associate Member
Breast Medicine Service
Memorial Sloan Kettering
Cancer Center
Associate Professor of Medicine
Weill Cornell Medical College
New York, NY

VK Gadi, MD, PhD

Professor and Director,
Medical Oncology
Associate Director,
Translational Medicine
University of Illinois Cancer Center
Chicago, IL

Yasmin Hasan, MD

Associate Professor
Department of Radiation
and Cellular Biology
Residency Program Director
Director, Gynecological Brachytherapy
University of Chicago Medical Center
Chicago, IL

Claudine Isaacs, MD, FRCPC

Professor of Medicine and Oncology
Associate Director
Clinical Research
Leader, Clinical Breast Cancer
Program
Lombardi Comprehensive Cancer
Center
Georgetown University
Washington, DC

Neil Iyengar, MD

Associate Attending
Memorial Sloan Kettering
Cancer Center
Associate Professor of Medicine
Weill Cornell Medicine
Associate Attending
Rockefeller University
New York, NY

Monique C. James, MD

Assistant Attending Psychiatrist
Department of Psychiatry and
Behavioral Sciences
Memorial Sloan Kettering
Cancer Center
New York, NY

Kevin Kalinsky, MD, MS

Director,
Glenn Family Breast Center
Winship Cancer Institute at
Emory University
Atlanta, GA

Reshma Mahtani, DO (MCI)

Chief of Breast Medical Oncology
Miami Cancer Institute
Baptist Health South Florida
Plantation, FL

Terry P. Mamounas, MD, MPH, FACS

Medical Director
Comprehensive Breast Program
Orlando Health Cancer Institute
Professor of Surgery
University of Central Florida
Orlando, FL

Heather McArthur, MD, MPH

Clinical Director of Breast Cancer
Komen Distinguished Chair in
Clinical Breast Cancer Research
UT Southwestern
Dallas, TX

Beryl McCormick, MD, FACR

Attending Radiation Oncologist
Department of Radiation Oncology
Memorial Hospital
Professor of Radiology
Weill Cornell Medical School
New York, NY

Babak Mehrara, MD

Chief of Plastic and
Reconstructive Surgery
Memorial Sloan Kettering
Cancer Center
New York, NY

Shanu Modi, MD

Member and Attending
Breast Medicine Service
Memorial Sloan Kettering
Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY

Elizabeth Morris, MD

Professor and Chair of Radiology
University of California, Davis
Davis, CA

Hyman B. Muss, MD

Mary Jones Hudson Distinguished
Professor of Geriatric Oncology
Professor of Medicine
University of North Carolina
Director of Geriatric Oncology
Lineberger Comprehensive
Cancer Center
Chapel Hill, NC

Anne O'Dea, MD

Associate Professor
Breast Medical Oncology
Director, Breast Cancer
Survivorship
University of Kansas School of
Medicine
Kansas City, KS

Elizabeth Poynor, MD, PhD

Clinical Professor of Obstetrics
and Gynecology
New York University, Langone
New York, NY

Andrew Seidman, MD

Attending Physician
Breast Medicine Service
Memorial Sloan Kettering
Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY

Tiffany A. Traina, MD

Vice Chair, Oncology Care
Section Head, Triple Negative Breast
Cancer Clinical Research Program
Associate Attending Physician
Breast Medicine Service
Memorial Sloan Kettering
Cancer Center
Associate Professor
Weill Cornell Medical College
New York, NY

PLANNING COMMITTEE AND MODERATOR BIOGRAPHIES



Maria Theodoulou, MD (Course Chair & Moderator) is recognized nationally and internationally for her breast cancer clinical research. Prior to joining New York Oncology Hematology, Dr. Theodoulou was an attending physician at Memorial Sloan-Kettering Cancer Center and Professor of Medicine at the Joan and Sanford Weill Medical College of Cornell University, both in New York City. Dr. Theodoulou is board certified in internal medicine as well as medical oncology.

Dr. Theodoulou's passion for clinical research is patient-driven, constantly searching for individualized therapy with minimal toxicities. She is a recipient of multiple prestigious awards including Leading Physicians of the World Top Breast Medical Oncologist in New York City 2019 and 2020, the Hally Yaccino Steiner Award–Susan G. Komen for the Cure Greater New York City, Lifetime Achievement Award Cyprus Federation of America, Irka Wozniak Memorial Lecture Award Sass Foundation for Medical Research, Commendation Office of Comptroller City of New York, Outstanding Physician Award Sass Foundation for Medical Research, Hellenic Medical Society Kalopothakes Distinguished Female Physician Award, ASCO Merit Award.

Dr. Theodoulou is presently the Program Director Breast Cancer Medicine at New York Oncology Hematology, the organizer and host/moderator of the NYOH Breast Cancer Symposium 2019, 2020, 2021, a nationally and internationally recognized CME educational program, as well as the host of the Fireside Virtual Chat Panel for Breast Cancer Survivorship Education for Patients and their family and friends.



Rakel Astorga, MD, is a breast surgeon in Hudson New York, and part of the Albany Medical Health Care System. She is an assistant professor in the Department of Surgery of Albany Medical College. Dr. Astorga is currently the Chief of Surgery for Columbia Memorial Hospital. She obtained her medical degree at The Autonomous University of Guadalajara

and completed Family Medicine Residency and General Surgery Residency at New York Medical College. She has worked in the Hudson Valley for almost 10 years as a general and breast surgeon.



Anna Boguniewicz, MD, is an Associate Professor of Pathology, Director of Cytology, and the Director of Residency Training in Pathology and Laboratory Medicine at Albany Medical Center, Albany New York.

She has served as the pathologist for the interdisciplinary breast tumor conference and the primary liaison for breast oncologists, surgeons, and radiologists for many years at AMC. She has also been active in teaching breast pathology to medical students, residents, and other allied health care professionals.



Rufus Collela, MD, is the Medical Director of NYOH and a Clinical Assistant Professor at Albany Medical College. He also serves as Chief Medical Officer for the American Cancer Society, Capital Region.



Tia D. Olds, MD, is a radiation oncologist at New York Oncology Hematology, a practice in The US Oncology Network, in Albany, NY. She earned her medical degree from Morehouse School of Medicine in Atlanta, interning at Saint Vincent's Medical Center in Staten Island, NY, and serving her residency in radiation oncology at SUNY Upstate Medical

Center in Syracuse, NY. A member of the American Society of Therapeutic Radiology and Oncology, Dr. Olds has earned multiple honors and awards, including the Morehouse School of Medicine Academic Achievement Award, the Janet Glasgow National Academic Citation, the Morehouse School of Medicine Award for Laudable Achievement in Internal Medicine, and recognition from the Alpha Omega Alpha Medical Honor Society.

FACULTY BIOGRAPHIES



Francis P. Arena, MD, FACP is the director of one of New York's largest oncology practice groups, The NYU Langone Arena Oncology Center, located in Lake Success, NY. He is also a Clinical Associate Professor of Medicine at New York University and an Adjunct Clinical Assistant Professor of Medicine at Cornell University Medical College.

Dr. Arena received his Bachelor of Science Degree from Fordham University and his Medical Degree from Cornell University Medical College. His internship and residency were carried out at New York Hospital/Memorial Hospital, after which Dr. Arena served as Chief Medical Resident and later as Hematology/Oncology Fellow at the Memorial Sloan-Kettering Cancer Center. He is Board Certified in Internal Medicine and Medical Oncology.

Because of his keen interest in cancer research and preventative cancer care, Dr. Arena helped establish and is the president of the SASS Foundation for Medical Research, which supports medical fellows at a number of hospitals. He is on the Advisory Board of "1 in 9", the Breast Cancer Coalition, and serves as a consultant for numerous pharmaceutical companies. Dr. Arena is widely published and has lectured extensively in his field. He is an Assistant Editor of the journal *Oncology* and was previously on the Editorial Board of the *Community Oncology* journal. Dr. Arena has been the recipient of multiple awards and citations for his work in oncology and breast cancer. Some of these awards include the David award given by *Networking* magazine, The Eileen Dryer Award by the Sass Foundation, and the Il Leone de San Marco award in medicine by the Italian -American League of Westchester and the Bronx. In the Spring of 2022, in recognition of Dr. Arena's service and leadership, the Sass Foundation has renamed the Sass-Arena Foundation for medical research. He was the first recipient of the Francis P. Arena Humanitarian Award and has been cited in repeated years as one of the top oncologists in the New York Metropolitan area by the *Castle Connolly* magazines and *Newsday*. Frank lives with his wife and wonderful children in Long Island, NY.

Dr. Arena was the co-producer of the Bermuda Pink Conference Cancer On Breast Cancer and was solely responsible for assembling the expert panel of doctors from NYU Langone, Weill Cornell, Sloan Kettering, North Shore LIJ, and Harvard Medical. He received the prestigious Bermuda International Citizenship Award for his moderating and production of the conference.



Edi Brogi MD, PhD, is an Attending Pathologist and the Director of Breast Pathology at Memorial Sloan Kettering Cancer Center. Dr. Brogi is a graduate of the University of Florence Medical School, in Florence, Italy, and holds a PhD in Clinical Pathophysiology from the Italian Ministry of Research. She trained in Anatomic Pathology at the Massachusetts General Hospital in Boston, Massachusetts, followed by two additional years as Chief Resident/ Graduate Assistant and Cytopathology fellow at the same institution. In July 2000, Dr. Brogi joined the staff at Memorial Sloan Kettering Cancer Center in New York City, NY, and has been practicing there ever since. Dr. Brogi's professional and research activities focus exclusively on the diagnosis, treatment, and study of breast diseases, particularly breast carcinoma, management of high-risk lesions of the breast, papillary neoplasms, and fibroepithelial lesions. She is recognized as an expert in the field nationally and internationally. Throughout her career, Dr. Brogi has been actively involved in education and teaching. She has trained over 40 breast pathology fellows and mentored junior breast pathologists, including up-and-coming leaders in the field. Dr. Brogi was a member of the United States and Canadian Academy of Pathology (USCAP) Education Committee (2012-2016) and co-directed the USCAP Long Course in Breast Pathology in March 2020. She is a member of the USCAP Board of Directors (2020-2023). Dr. Brogi was an Officer of the International Society of Breast Pathology from 2012-2016, and President of the Society from 2017-2019. Dr. Brogi has published over 250 original articles, review articles, and book chapters predominantly focused on breast diseases. She is Associate Editor of *Rosen's Breast Pathology By Needle Core Biopsy* textbook (4th edition, 2017) and *Rosen's Breast Pathology* textbook (4th edition, 2014 and 5th edition 2020). Dr. Brogi is an expert member of the Editorial Board of the World Health Organization *Blue Book on the Classification of Breast Tumors* (5th Edition).



Hiram S. Cody III, MD, is a graduate of the Columbia University College of Physicians and Surgeons, completed a surgical residency at The Roosevelt Hospital and Surgical Oncology Fellowship at Memorial Sloan-Kettering Cancer Center, where he is currently Attending Surgeon on the Breast Service (Department of Surgery), Member (Memorial Hospital), and Professor of Surgery at the Weill Cornell Medical College. He is the Past President of the American Society of Breast Surgeons and the author of more than 250 publications.



Chau T. Dang, MD is an attending physician on the Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY. With an interest in evaluating combination therapies that include anti-HER2 drugs with chemotherapy in the treatment of patients with early-stage and metastatic HER2-positive breast cancer, Dr. Dang focuses on developing more effective and less toxic treatment strategies for women with this disease. Her research and an investigator-initiated trial at Memorial Sloan Kettering have led to the widespread use and National Comprehensive Cancer Network (NCCN) endorsement of a dose-dense, anthracycline/taxane-containing chemotherapy regimen followed by trastuzumab in patients with early-stage HER2-positive breast cancer. A second investigator-initiated study that evaluated dual anti-HER therapy with trastuzumab and pertuzumab and chemotherapy for patients with HER2-positive metastatic breast cancer led to the NCCN endorsement of this regimen as a standard option in treating patients with metastatic HER2-positive breast cancer. A third investigator-initiated study on dual anti-HER2 therapy with trastuzumab and lapatinib with chemotherapy also had an impact on research worldwide. Dr. Dang and her colleagues are currently leading other research trials, both locally and internationally that focus on the unique cardiac toxicities of anthracyclines and anti-HER2 agents. To allow for improved patient selection and monitoring, she studies cardiac biomarkers, with a future goal of facilitating early interventions to minimize acute and late cardiac effects of cancer treatment.

Dr. Dang is board-certified in internal medicine and medical oncology with clinical expertise in breast cancer. She received her MD at the Medical University of South Carolina followed by Internal Medicine Residencies at Allegheny General Hospital/Medical College of Pennsylvania and Fellowships in Hematology/Oncology at Memorial Sloan Kettering Cancer Center.



Azeez Farooki, MD, is an Attending Physician on the endocrinology service at Memorial Sloan Kettering. He also has the appointment of Associate Clinical Professor at Weill Cornell Medical College. He has taught and served as a research mentor for numerous medical students, residents, and fellows. His clinical and research focuses include both benign bone disease (bone loss due to cancer therapies) and malignant bone disease, including hypercalcemia of malignancy. He attended medical school at New Jersey Medical School (UMD-NJMS) in Newark, NJ, and completed his internal medicine residency at Temple University Hospital in Philadelphia. He completed his endocrinology fellowship at Robert Wood Johnson Medical School (UMD-RWJMS). He has authored book chapters and review articles on benign and malignant bone diseases. He has served as expert faculty for the American Cancer Society “cancer and bone” ECHO sessions and served on the NCCN Bone Health and Cancer Care Task Force. He has published letters in the *Lancet*, the *New England Journal of Medicine*, *Diabetes Care*, and the *Journal of Clinical Oncology*. He has authored an invited commentary for *Annals of Internal Medicine*. He has published original research in the *Journal of Clinical Endocrinology and Metabolism* and several other journals. He has served on the PI3 kinase, Akt inhibitor, MTOR inhibitor Task Force (addressing hyperglycemia and hyperlipidemia as adverse effects of these anti-cancer agents) to the Investigational Drug Steering Committee of the National Cancer Institute of the National Institutes of Health (NIH). He has spoken at numerous conferences (National Comprehensive Cancer Network, Endocrine Society Meet the Professor, and the American Academy of Clinical Endocrinologists) and delivered many grand rounds.



Monica Fornier, MD is an Associate Member of the Breast Medicine Service of Memorial Sloan Kettering Cancer Center, and specializes in the treatment of patients with breast carcinoma as well as bone health. She is also an Associate Professor at Weill Cornell Medical College. Dr. Fornier graduated summa cum laude from the University of Milan School of Medicine; she pursued her Oncology fellowship at the National Cancer Institute of Milan, and a second fellowship at Memorial Sloan Kettering Cancer Center in New York. She conducts clinical research in breast cancer, with particular regard to novel strategies for the preservation of bone health. Dr. Fornier is an active member of various national and international scientific groups, including the American Society of Clinical Oncology and the European Society of Medical Oncology. Dr. Fornier has numerous publications to her name and has presented data at several meetings.



V.K. Gadi, MD, PhD, is a Professor and Director of Medical Oncology at the University of Illinois Chicago and an Associate Director at the University of Illinois Cancer Center. He spent 10 years at the University of Alabama at Birmingham completing undergraduate, graduate, and medical school followed by 20 years at the University of Washington and Fred Hutch Cancer Center in post-graduate training, later rising through the ranks to Associate Professor before departing for Chicago at the start of the COVID-19 pandemic. His laboratory research has focused on the development of diagnostics, therapeutics, and immunotherapy for cancer. Several of these technologies have been licensed to early-stage biotechnology companies, including several of which he founded, and some innovations are now in routine clinical care for hard-to-treat cancers. His clinical practice is focused on breast cancer. As a translational investigator, he develops clinical trials for breast and other cancers across all stages of study and all stages of disease. Notable, he has authored two trials that were first in human cell therapy studies. Members of his trainee diaspora have gone on to academic professorships, industry leadership, and entrepreneurship. As an educator, he has taught and lectured at all levels of engagement from lay audiences to specialized conferences for experts both in the United States and Abroad.




Yasmin Hasan, MD, is the Director of the Gynecological Brachytherapy Program and the clinical and academic lead for the gynecological cancer program within the Department of Radiation and Cellular Oncology at the University of Chicago. She is also the residency program director. Through clinical research focused on quality outcomes and collaboration interdepartmentally, Dr. Hasan has developed a niche in women's cancers, including breast cancer. This program provides patients the opportunity for comprehensive care, including enrollment in clinical trials. Dr. Hasan is also the clinical lead for hematologic malignancies including lymphomas and leukemia. Dr. Hasan has more than 30 published abstracts, 6 book chapters, several senior or primary author publications, and more than 40 peer-reviewed papers.




Claudine Isaacs, MD, FRCPC, is a Professor of Medicine and Oncology, Associate Director for Clinical Research, and Leader of the Clinical Breast Cancer Program at the Lombardi Comprehensive Cancer Center (LCCC) at Georgetown University. She is also the Medical Director of the Jess and Mildred Fisher Center for Hereditary Cancer and Clinical Genomics Research. She has extensive experience in the conduct of clinical trials focusing on all aspects of breast cancer and currently serves as Co-Chair Endocrine Resistance Working Group of the Translational Breast Cancer Research Consortium (TBCRC) and as Co-Chair of the Clinical Trials Operations Working Group for the I-SPY 2 Trial. She has authored over 200 peer-reviewed publications and edited two textbooks. She has served on a number of national committees including the Scientific Program Committees at ASCO, the ASCO Breast Cancer Guideline Advisory Group, the Breast Oncology Local Diseases Task Force of the Breast Steering Committee of the NCI.



Neil M. Iyengar, MD, is a board-certified Medical Oncologist and clinical-translational researcher at Memorial Sloan Kettering Cancer Center (MSKCC) where he specializes in the care of patients with breast cancer. He also holds joint research appointments at the Rockefeller University Center for Clinical and Translational Science and Weill Cornell Medicine in New York. Dr. Iyengar received his undergraduate and medical degrees from the University of Illinois at Chicago accelerated degree program where he graduated with the College's highest honors (University Scholar). He completed residency training in Internal Medicine at the University of Chicago Medical Center followed by a fellowship in medical oncology and hematology at MSKCC. He now holds a faculty position as an Associate Attending on the Breast Medicine Service at MSKCC. Dr. Iyengar's research program investigates interventions to improve metabolic health as a strategy to reduce breast cancer risk and mortality. His group is testing the anti-cancer effects of structured exercise and nutritional interventions in people at high risk or diagnosed with breast cancer. Dr. Iyengar's research is also investigating the use of drugs that treat metabolic disorders, such as diabetes and obesity, to improve the effectiveness of cancer therapies. In an effort to rapidly translate this work, Dr. Iyengar also leads the Healthy Living Program, a novel cancer care model that aims to translate research findings from lifestyle intervention trials into clinical practice during and after cancer therapy. His work has been recognized and awarded by several organizations, including research grants from the National Cancer Institute, American Cancer Society, the Breast Cancer Research Foundation, Conquer Cancer the ASCO Foundation, and others. He has published numerous original research articles and has been an invited speaker at several international conferences.



Monique C. James, MD, is a medical doctor of psychiatry specializing in psycho-oncology and women's health. After adult psychiatry residency at the University of California, San Francisco (UCSF), she then completed her fellowship in consult-liaison psychiatry at Memorial Sloan Kettering Cancer Center (MSK) and New York Presbyterian Weill Cornell Medical Center, where she has stayed on as faculty in a duly appointed role. Her outpatient practice is comprised mostly of patients with breast cancer at MSK, and she also cares for inpatients at MSK with all types of cancer. She is originally from Miami, Florida but has lived in several parts of the United States and is happy to call New York home at this time.



Kevin Kalinsky, MD, MS, is an Associate Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Dr. Kalinsky serves as the director of the Glenn Family Breast Center at Winship where he is tasked with fulfilling the vision to improve breast cancer outcomes by aligning research and education with cancer treatment and prevention. Dr. Kalinsky received his medical degree from the Medical University of South Carolina and a Masters's in Biostatistics, Patient-Oriented Research Track from Columbia University Mailman School of Public Health. His training included a Residency and Medical Oncology Fellowship at Tufts-New England Medical Center, Breast Cancer Research Fellowship at Massachusetts General Hospital, and Breast Cancer Advanced Oncology Fellowship at Memorial Sloan-Kettering Cancer Center. Dr. Kalinsky's research involves the development of early-phase clinical trials to assess novel therapeutics in breast cancer based on tumor genomics. He has received the NCI Cancer Clinical Investigator Team Leadership Award, Physician of Impact Award by Komen Greater NYC, Ewig Clinical Scholar Teaching Award, and SWOG Career Engagement Award.



Reshma L. Mahtani, DO, is a medical oncologist practicing in South Florida. She serves as Chief of Breast Medical Oncology at the Miami Cancer Institute, Baptist Health South Florida (a Memorial Sloane Kettering affiliate). Her practice is limited to breast cancer. After completing her master of science degree in neuroscience at the University of Connecticut, Dr. Mahtani went on to the University of New England College of Osteopathic Medicine, where she received her medical degree. She completed an internship at Greenwich Hospital, a Yale affiliate, in Greenwich, Connecticut, and undertook residency training at St. Vincent's Catholic Medical Center in New York, where she also completed her fellowship. Prior to assuming her role at the Miami Cancer Institute, Dr. Mahtani was an Associate Professor of Medicine and Co-Leader of the Breast Cancer Program at Sylvester Comprehensive Cancer Center, University of Miami, where she oversaw the clinical trial program across the network. She is an active

continued →

clinical researcher and her research focuses on novel therapies for the treatment of breast cancer. She has made significant scientific and clinical practice contributions with numerous first-author publications in peer-reviewed journals. She has served on the ASCO Quality Oncology Practice Initiative (QOPI) Steering Committee and as a member of the editorial board of The Breast Journal and Practice Update (an online medical education platform for physicians). She has been Program Director for several officially licensed Best of ASCO programs and is the Director of the ASCO Highlights series. She has a passion for medical education and founded a medical education initiative to ensure that physicians in South Florida know about the latest cancer treatments and can provide evidence-based care. Finally, she is involved in several initiatives that enhance patients' access to healthcare, as well as community collaborations for education and advocacy.



Eleftherios (Terry) P. Mamounas, MD, MPH, FACS, is the Medical Director of the Comprehensive Breast Program at Orlando Health Cancer Institute, Professor of Surgery at the University of Central Florida, and Clinical Professor of Clinical Sciences, Florida State University College of Medicine. He is Chair of the NRG Oncology Breast Committee and past Chair of the NSABP Breast Committee. He received his medical degree from the University in Athens in Greece and a Master of Public Health (Epidemiology) from the University of Pittsburgh. Following his general surgery residency, he completed an oncology research fellowship at the University of Pittsburgh and a surgical oncology fellowship at Roswell Park Cancer Institute in Buffalo, New York. He has authored or co-authored over 400 abstracts, manuscripts, and book chapters, and he has given numerous presentations on breast cancer at various regional, national, and international symposia. His clinical research has focused on the surgical and adjuvant treatment of early-stage breast cancer.



Heather McArthur, MD, MPH is the Clinical Director of Breast Cancer at the University of Texas Southwestern Medical Center (UTSW) and Komen Distinguished Chair in Clinical Breast Research. Dr. McArthur is a medical oncologist with a clinical practice dedicated to the care of patients with breast cancer. Her research activities are focused on innovations in the diagnosis and treatment of breast cancer, with a particular interest in novel immune therapy strategies. For example, she is currently evaluating the impact of tumor destruction with freezing (cryoablation) or radiation in combination with immune stimulation for the treatment of women with early-stage breast cancer. It is hoped that by augmenting one's immune response to the unique biologic features of one's tumor, an affected individual may develop long-term immunity against their tumor, and thus, be cured. Dr. McArthur completed formal medical oncology training in Canada where she was awarded a highly competitive grant that funded an advanced fellowship at Memorial Sloan Kettering Cancer Center (MSKCC) in New York. Thereafter, she joined MSKCC as faculty where she developed the institutional breast cancer immunotherapy program before joining CSMC in 2016 and UTSW in 2021. She has a Master's in Public Health with a focus on clinical trial design from Harvard University and has mentored many medical students, residents, fellows, and junior faculty in the conduct and reporting of several studies - two of which directly informed the National Comprehensive Cancer Network treatment guidelines. Dr. McArthur has held several leadership positions in the field including Co-Chair of a Breast International Group Immunotherapy Taskforce, member of a National Cancer Institute (NCI) Breast Cancer Immuno-Oncology (IO) Working Group, member of an NCI Breast Cancer IO Task Force, and member of an Alliance for Clinical Trials in Oncology IO Committee. She has served the American Society of Clinical Oncology (ASCO) on the Annual Meeting IO Scientific Committee, the YIA/CDA Grant Selection Committee, the Breast Cancer Symposium Program Committee, the Annual Meeting Grant Writing Workshop, a Guideline Expert Panel, and Educational Book Expert Panels. She has participated in the ASCO Leadership Development Program; reviewed manuscripts for various high-impact journals; authored numerous articles, and served on many study steering committees. She has designed, conducted, and reported on many studies in breast cancer and is currently the co-PI for a large, randomized, international phase 3 study exploring adjuvant chemotherapy with or without immune therapy for the treatment of triple-negative breast cancer (IMpassion030).



Beryl McCormick, MD, FACR, has specialized in the treatment of Breast Cancer with radiation since completing her residency at Memorial Sloan Kettering Cancer Center. In the course of her career, she was a founding member of the NCCN Breast Guidelines Committee, serving with that group for over 20 years, the Chair for 10 years of the RTOG Breast Committee, and the Acting Chairman of the Department of Radiation Oncology for over 3 years, until the present chair was named. Her main research contributions have been thru her work in cooperative groups, namely RTOG and NRG. She ensured that the CALGB 9343 “Elderly Trial” reached accrual with her RTOG committee’s strong support, demonstrating that older women with Stage I breast cancer had minimal benefit from radiation and initiated the first cooperative group trials of Partial Breast Irradiation (PBI). Once those initial feasibility trials were published, she worked closely with the NCI and NSABP group in her role as chair of the RTOG Breast Committee, to launch the large prospective trial comparing whole breast radiation to PBI, the B-39 trial. She is also the PI of the RTOG DCIS Trial for “good Risk” breast cancer patients, also showing that breast radiation could safely be omitted in many patients who presented with so-called “good risk” DCIS. She is a dedicated teacher for medical students and residents, a mentor for junior faculty, and has made numerous “Best Doctor” lists throughout her career.




Babak J. Mehrara, MD, is the Chief of the Plastic and Reconstructive Surgery Service and the Peter G. Cordeiro Endowed Chair in the Department of Surgery at Memorial Sloan Kettering Cancer Center (MSK), with a joint appointment as Professor of Surgery at Weill Cornell Medical College. Dr. Mehrara is an oncologic reconstructive surgeon with a broad background in both the clinical management and the biology of cancer. He has authored more than 250 peer-reviewed publications and serves as the Director of the National Institutes of Health-funded Lymphatic Biology Laboratory at MSK.




Shanu Modi, MD, is a Professor of Medicine in the Department of Medicine at Weill Cornell Medical College in New York, New York. She is also a Full Member and Attending on the Breast Medicine Service at Memorial Sloan Kettering Cancer Center (MSKCC) in New York, New York. She received her medical degree from the University of Alberta in Edmonton, Canada where she also completed a residency in internal medicine. She followed this with subspecialty training in medical oncology at the Cross Cancer Institute and subsequently completed a 4-year fellowship in breast cancer research at MSKCC. She has been a full-time faculty member on the Breast Medicine Service at MSKCC since 2005. She has a clinical practice dedicated to the treatment of patients with breast cancer and has a clinical research career in the development of HER2 targeted therapies and is currently the Section Head for HER2 Breast Cancer Program for the Breast Medicine Service at Memorial Sloan Kettering Cancer Center. In her earliest work, she led the first human study of Trastuzumab Emtansine (T-DM1), the first antibody-drug conjugate (ADC) for HER2+ breast cancer, at MSKCC and conducted follow-up phase 1b and 2 trials which ultimately led to the FDA approval for TDM1 in 2013. Over the past decade, she has led or participated in numerous studies of novel HER2 targeting agents or strategies, including monoclonal antibodies, T-Cell Bispecific agents, PI3k inhibitors, tyrosine kinase inhibitors, checkpoint blockade inhibitors, HSP90 inhibitors, and HER3 monoclonal antibodies. Her work is focused on the clinical development of the new generation HER2 targeted ADC, Trastuzumab Deruxtecan (T-Dxd). She led the pivotal phase 2 trial of this ADC for HER2+ MBC and published her findings in the NEJM. This work led to accelerated FDA approval in 2019. She has recently presented and published ground-breaking phase 3 data for T-Dxd in the treatment of patients with HER2-Low MBC, which has the potential to be the first HER2 targeted therapy approved for this patient population. Dr. Modi has been a member of the Expert Committee to establish Guidelines for Patients with Advanced HER2+ Breast Cancer, where she serves on the Breast Cancer Consensus Panel. She is also a member of the Scientific Committee for the European Society of Medical Oncology (ESMO) as part of the metastatic breast cancer track responsible for abstract selection. She has also been the chair and member of the Scientific Program Committee for HER2 Positive Breast Cancer from 2013-2016 and a member of the grant selection committee for the American Society of Clinical Oncology (ASCO) from 2013 to 2015. She received the Conquer Cancer Foundation Advanced Clinical Research Award in 2009 for her work in Heat Shock Protein Inhibition. And was awarded and held the Patricia and James Cayne Chair for Junior Faculty at MSKCC from 2009-2012.



Elizabeth Morris, MD, is Professor and Chair of Radiology at the University of California, Davis (UCD) School of Medicine. Dr. Morris graduated summa cum laude from UCD in Biochemistry and received her medical degree from the University of California, San Francisco (UCSF). She completed her residency at Weill Cornell Medical College (WCMC) and a body/breast imaging fellowship at Memorial Sloan Kettering Cancer Center (MSKCC) where she remained on faculty until December 2020 and where she was the Chief of the Breast Imaging Service and Larry Norton Endowed Chair. Dr. Morris is a fellow of the American College of Radiology (ACR), Society of Breast Imaging (SBI), and International Society of MR in Medicine (ISMRM) and is past president of the SBI. She is the inaugural Equity Diversity & Inclusion officer of the ISMRM and co-chair of the Women of ISMRM (WISMRM). Her research focus is on how best to use newer techniques such as MRI for early breast cancer detection and to improve the workup of breast lesions. In collaboration with her colleagues, she has written over 230 papers, 40 chapters, and 5 books about breast disease with an emphasis on the use of MRI. She has lectured widely both nationally and internationally at over 320 conferences. She has mentored over 50 international research fellows. She has grants from NCI, RSNA, Komen Foundation, and Breast Cancer Research Foundation. She has authored a book "Breast MRI: Diagnosis & Intervention". Her recent research efforts have involved looking at imaging biomarkers to assess risk and treatment response.



Hyman Bernard Muss, MD, holds the Mary Jones Distinguished Professorship in Geriatric Oncology, Department of Medicine, the University of North Carolina at Chapel Hill. He is also the Director of Geriatric Oncology at the Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina.



Anne O'Dea, MD, is an Associate Professor at the University of Kansas Medical Center where she also serves as the Medical Director for both Breast Cancer Survivorship and Breast Cancer Clinical Research Program Services. Her primary focus in clinical practice is on the treatment of breast malignancy as well as breast cancer risk assessment, prevention, and survivorship. Her clinical practice spans the state of Kansas and across the region serving women with breast cancer from urban and rural communities. She has dedicated her career to promoting breast screening, genetic counseling, and preventive measures such as a healthy diet, weight management, and exercise. Dr. O'Dea's research interests span across the cancer control continuum and in 2016 she was responsible for the largest number of women with breast cancer enrolled in breast cancer treatment and supportive care trials. She serves as a co-investigator for several treatment and survivorship trials, including those focused on triple-negative breast cancer, advanced breast cancer, and survivorship issues including lifestyle modification and cognitive impairment.




Elizabeth A. Poynor, MD, PhD is a gynecologic oncologist and advanced pelvic surgeon, with a deep understanding of women's health. Her expertise is in the management of complex women's health issues. She focuses on the management of midlife women's health concerns and aging strategies, hormonal and endocrinological health concerns, diagnostic and prevention of illness strategies for women, and complex pelvic surgery including surgical oncology and deep excision of endometriosis. Through her extensive surgical and medical background, she is able to care for women in a holistic fashion and uniquely employs both medical and surgical approaches for women's health. After completing advanced surgical training in gynecology, gynecologic oncology, and advanced pelvic surgery at Memorial Sloan-Kettering Cancer Center and maintaining a successful surgical practice there for more than a decade, she decided to focus exclusively on the care of women in a more comfortable, private, comprehensive and integrative setting. After establishing her private practice, she was noted in 2007 and 2008 to be a Castle Connolly Guide Top Doctor for the New York Metro Area for gynecologic oncology. She was noted to be a *New York Magazine*, Castle Connolly Top Doctor in New York in 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021 and 2022. She is also listed in the Best Doctors in America. She was the first gynecologic surgeon at Lenox Hill Hospital to employ robotic surgery, and she maintains an appropriately high surgical volume of robotic surgery cases at Northwell Health and NYU Langone Medical Center. Dr. Poynor graduated magna cum laude from Princeton University in 1984. She then graduated from Columbia College of Physicians and Surgeons in 1988 and completed her residency training in Obstetrics and Gynecology at the University of Pennsylvania in 1992. Dr. Poynor completed her fellowship in gynecologic oncology in 1995 at Memorial Sloan-Kettering Cancer Center and remained on the surgical attending staff until July of 2006. While developing and maintaining a busy surgical practice as an Assistant Attending Surgeon at Memorial Sloan-Kettering Cancer Center and Assistant Professor of Obstetrics and Gynecology at Cornell Weill Graduate School of Medical Sciences, she also obtained a PhD in cell biology and genetics from Cornell. Dr. Poynor is Board Certified in Obstetrics and Gynecology and Gynecologic Oncology. In June of 2006, after amassing a vast experience in radical pelvic and minimally invasive pelvic surgery, Dr. Poynor established her solo private practice in gynecologic oncology and pelvic surgery in Manhattan. This move was made in order to provide her patients with leading-edge, top-quality care in a patient-centric, calm, integrative and compassionate fashion. In addition to providing surgical and medical care to the highest standards in her field, she provides a distinct focus on the importance of the patient-physician relationship and a cohesive, comprehensive approach to health and wellness. She is currently a Clinical Professor of Obstetrics and Gynecology at NYU Langone. Dr. Poynor was brought up in a family which was based in a small town in central Oklahoma where the culture of profound respect for life, nature, harmonious relationships with the world, and the importance of the communication between mind, body, and spirit was lived, and this has naturally influenced how she approaches her practice of the art and science of medicine. The philosophy that caring for fellow human beings is based on profound respect, and that every life is a gift to be treated with gratitude and respect, forms the foundation for her practice of medicine. Her practice is the intersection of science and the art of medicine. Over the years Dr. Poynor has co-authored numerous publications and book chapters on topics in gynecology and gynecologic oncology and has lectured nationally, internationally, and through the national media. As a surgeon-scientist her work involved translating basic science principles into clinically meaningful treatments and she served as Director of Translational Research for the Gynecology Service at Memorial Sloan-Kettering Cancer Center. Dr. Poynor has also served as an investigator in numerous clinical trials relating to the surgical, medical, and biologic treatment of gynecologic cancers and has participated in national leadership positions in gynecologic oncology including the Committee on Experimental Medicine in the Gynecologic Oncology Group. She is a leader in robotic and minimally invasive surgery in Manhattan. She currently performs surgery at NYU Langone Medical Center in New York, and Northwell Health Lenox Hill Hospital. Dr. Poynor provides comprehensive care in an allopathic fashion with an integrative approach for complex gynecologic and endocrinological conditions. Not only are traditional therapies offered, natural approaches including lifestyle and nutritional approaches are employed. Medical, integrative and surgical approaches are reviewed for each individual. Through her extensive experience in the treatment of women's cancers and transition into the private setting, she is able to provide leading-edge care in an unhurried and calm atmosphere so that treatment plans and options can be discussed in a private, thorough, and highly educated fashion. There is a focus on minimally invasive surgery in the practice and advanced laparoscopic techniques are employed. In addition to traditional

continued →

outcomes evaluation of operative procedures, there is also attention directed towards cosmetic and quality of life outcomes for patients who require surgery. Dr. Poynor's practice also focuses on the care of the woman who is at elevated risk to develop cancer based on an abnormal Pap smear, her personal medical history, or family history of cancer. She has special expertise in the complex management of women and their families who have a genetic predisposition to developing cancers including breast cancer and gynecologic malignancies. Dr. Poynor also provides gynecologic care for women who currently have or have survived cancer, and may be experiencing side effects from prior or ongoing treatments. A large portion of her practice is devoted to the management of menopausal symptoms and the sexual health of women who may or may not be candidates for hormone replacement therapy. Dr. Poynor has thus developed a special interest in the management of health and quality of life issues related to menopause. Dr. Poynor has had a lifelong interest in the role of hormonal health in overall wellbeing, menopause, aging, and complex gynecologic issues such as PMS/PMDD, endometriosis, pelvic floor dysfunction, and PCOS. She has developed special expertise employing not only traditional therapies but also bio-identical and more natural therapies to enhance healing and quality of life. Dr. Poynor is a respected and sought-after source for the popular press and has been quoted in such publications as *Town and Country*, *More*, and *Redbook*. She has also appeared as an expert commentator on CBS, *Good Morning America*, Fox, MSNBC, *Dr. Oz*, the *Today Show*, and WCBS. She has served on multiple boards relating to women's health including Women's Voices for Change, Cancer Shmancer, TEAL (Tell Every Amazing Lady), and Sharsheret. She actively sits on the medical advisory board of In-Kind Space and is engaged with Elektra Health; both are startup companies dedicated to the engagement of technology to improve women's health. She is a frequent commentator for online health publications. She frequently teaches young physicians in training at Lenox Hill Hospital through operative training and didactics. She is a supporter of the use of social media to improve health for women and can also be followed on Instagram and Twitter. Her most recent endeavor is the development of the Poynor Health Collective in order to distribute leading-edge clinical information and products relating to integrative and allopathic approaches to women's health and wellness. Her research focus is on the importance of nutrition, exercise, stress management, and the gut microbiome in the maintenance of wellness and prevention of disease in women.



Andrew D. Seidman, MD, is an Attending Physician for the Breast Medicine Service at Memorial Sloan Kettering Cancer Center, and a Professor of Medicine at Weill Cornell Medical College. Dr. Seidman earned his medical degree from Hahnemann University School of Medicine in Philadelphia, Pennsylvania in 1985. He completed a residency in Internal Medicine at the Pennsylvania Hospital. Dr. Seidman then completed a fellowship in Medical Oncology and Hematology at Memorial Sloan Kettering Cancer Center in New York. Dr. Seidman's clinical research in the development of taxanes for breast cancer has impacted clinical care worldwide. He has authored or co-authored more than 200 peer-reviewed articles, reviews, and book chapters, as well as over 160 abstracts, has served on the editorial boards of over a dozen leading oncology journals and has lectured at innumerable national and international conferences and symposia on breast cancer-related topics. Dr. Seidman is a Past-President of the American Society of Breast Disease, and the recipient of a Career Development Award from the American Society of Clinical Oncology (ASCO) for his work developing taxanes for breast cancer. He has received the Gay Clark Stoddard Award from the Susan G. Komen Foundation for excellent and compassionate care of patients with breast cancer, the Jacob Ehrenzeller Award from Pennsylvania Hospital for Academic Excellence, and a Distinguished Alumnus Award from the Hahnemann School of Medicine. He chaired a Working Group for the National Cancer Institute's Breast Cancer Steering Committee on Meaningful and Appropriate Endpoints for Clinical Trials in Metastatic Breast Cancer (*J Clin Oncol* 2018). He serves as the Medical Director of MSKCC's Bobst International Center. He has served on the ASCO Communications and Education Committees, as Associate Chair of Academic Administration at MSKCC, as Senior Breast Cancer Advisor to the MSKCC-IBM Watson Collaboration, and as the Medical Director of MSKCC's Bobst International Center. Dr. Seidman has served on the Oncology Drug Advisory Committee to the U.S. Food and Drug Administration. He currently leads an active translational research program focused on novel systemic treatment strategies for breast cancer brain metastases.



Tiffany A. Traina, MD, is an Associate Attending Physician on the Breast Medicine Service at Memorial Sloan Kettering Cancer Center. She serves as a Vice Chair for the Department of Medicine and Section Head of the Triple Negative Breast Cancer Clinical Research Program. She is Co-Chair of the MSK Outpatient Operations Committee and has served as the Clinical Director of the Breast Medicine Service. She is an Associate Professor of Medicine at Weill Cornell Medicine in New York City. Her research program centers on the development of therapies for patients with breast cancer, with a particular focus on Triple Negative Breast Cancer and the role of the androgen receptor. Dr. Traina has served on numerous ASCO committees including the Scientific Program Committee for the ASCO Triple Negative Breast Cancer/Cytotoxics/Local Therapy track and she is past Chair for the ASCO Membership Committee 2020-2021 as well as the Co-Chair of the Breast Cancer Guidelines Advisory Group. Dr. Traina is a graduate of the 2016-2017 ASCO Leadership Development Program and the MSK Physician Executive Development Program. She is a founding member of the Translational Breast Cancer Research Consortium Triple Negative Breast Cancer Working Group. Her research efforts have led to many publications, peer-reviewed funding, and competitive funding. She has received recognition for her teaching from Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine and has been acknowledged with the Hally Yaccino Steiner Award from the Susan G. Komen Breast Cancer Foundation and the Hero Award from the Triple Negative Breast Cancer Foundation.

**PLEASE BE SURE TO VISIT OUR
SPONSORS AND EXHIBITORS ON THE 1ST FLOOR**

**IF YOU ARE ATTENDING THE CONFERENCE
VIRTUALLY ONLINE, LOG INTO THE CONFERENCE
WEBSITE TO ACCESS THE ANCILLARY EVENTS**

bcsny2022.com

Thank you to our Educational Grant Supporter:

CME SYMPOSIUM
**New Opportunities for Targeting Therapy
in HER2-Positive Breast Cancer**

**September 25, 2022
11:30am – 12:30pm**

Location: Performance Hall 2nd Floor
Virtual: <https://www.bcsny2022.com/general-session>



Chau T. Dang, MD
MSK Westchester
Medical Oncology
Attending,
Breast Medicine Service
Memorial Sloan Kettering
Cancer Center



VK Gadi, MD, PhD
Professor and Director
Medical Oncology
Associate Director
Translational Medicine
University of Illinois
Cancer Center
Chicago, IL



Neil Iyengar, MD
Associate Attending
Memorial Sloan Kettering
Cancer Center
Associate Professor of Medicine
Weill Cornell Medicine
Associate Attending
Rockefeller University
New York, NY



This activity is supported by an educational grant from Seagen, Inc.

THANK YOU TO OUR PRODUCT THEATER SPONSORS

September 23, 2022 – 8:45am ET

LOCATION: West Room, 1st Floor

VIRTUAL: <https://www.breakoutroom1.com>

The non-CME Ancillary Event titled:

It's Time to Give NERLYNX a Second Look: A Case-Based Discussion on Reducing Recurrence in HER2+ eBC1-3

EVENT DESCRIPTION:

Program Featuring: (a) clinical case studies based on actual NERLYNX patients with HER2+eBC with and without a pCR (b) Final efficacy results from the pivotal ExteNET trial: primary endpoint, descriptive analyses of iDES, OS, and CNS (c) Safety information: an evolved approach using dose escalation.

PROVIDED BY: Puma Biotechnology, Inc.



GUEST SPEAKER:

Vijayakrishna Gadi, MD, PhD

*Medical Oncologist Professor and
Director of Medical Oncology
Department of Medicine Associate Director,
Translational Oncology
University of Illinois in Chicago Medical Center,
Winnetka, IL*

September 23, 2022 – 12:00pm ET

LOCATION: West Room, 1st Floor

VIRTUAL: <https://www.breakoutroom2.com>

The non-CME Ancillary Event titled:

Learn More About an FDA-Approved Treatment for Metastatic Triple-Negative Breast Cancer

EVENT DESCRIPTION:

Gilead Sciences, Inc., is proud to present a live meeting on metastatic triple-negative breast cancer.

PROVIDED BY: Gilead Sciences, Inc.



GUEST SPEAKER:

Karen L. Tedesco, MD

*Medical Oncologist and Hematologist
Hereditary Risk Assessment Program Director
New York Oncology Hematology
Albany, NY*

September 24, 2022 – 8:00am ET


LOCATION: Performance Hall, 2nd Floor

VIRTUAL: <https://www.breakoutroom3.com>

The non-CME Ancillary Event titled:

A Treatment option for Patients with HER2+ Metastatic Breast Cancer (MBC)

PROVIDED BY: Seagen, Inc.



GUEST SPEAKER:

William Sikov, MD

*Obstetrics and Gynecology, Clinician Educator
Professor of Medicine, Clinician Educator
Medical Oncologist
Breast Health Center of Women and Infants Hospital
of Rhode Island*

September 24, 2022 - 8:45am ET

LOCATION: West Room, 1st Floor

VIRTUAL: <https://www.breakoutroom4.com>

The non-CME Ancillary Event titled:

A First-Line CDK4/6 Inhibitor Combination Therapy: Clinical Trial Evidence Complemented by a Real-World Effectiveness Evaluation

EVENT DESCRIPTION:

This industry sponsored program will share evidence from routine clinical practice, which complements findings from the randomized clinical trials PALOMA-2 and PALOMA-3. Real-world data for HR+/HER2-aBC/mBC patients treated with CDK4/6 inhibitor combination therapy will also be evaluated.



PROVIDED BY: Pfizer, Inc.

GUEST SPEAKER:

Anne O'Dea, MD

*Medical Director
Breast Cancer Survivorship Center
Assistant Professor of Oncology
University of Kansas Cancer Center*

September 24, 2022 – 11:30am ET

LOCATION: West Room, 1st Floor

VIRTUAL: <https://www.breakoutroom5.com>

The non-CME Ancillary Event titled:

The Efficacy and Safety of ENHERTU



EVENT DESCRIPTION:

Please join us for an informative, expert-led discussion presented by Daiichi Sankyo, Inc. and AstraZeneca to be among the first to explore the HER2+ and HER2Low mBC indications.

PROVIDED BY: Daiichi Sankyo, Inc., DSI/AstraZeneca

GUEST SPEAKER:

Francis Arena, MD

NYU Langone

September 25, 2022 – 8:00am ET

LOCATION: Performance Hall, 2nd Floor

VIRTUAL: <https://www.breakoutroom6.com>

The non-CME Ancillary Event titled:

Explore Data for an FDA-approved Treatment Option in HR+, HER2- Breast Cancer in Certain Adjuvant or Metastatic Settings



PROVIDED BY: Lilly USA, LLC

GUEST SPEAKER:

Peter A. Kaufman, MD

*Professor of Medicine,
Hematology/Oncology Division Department of Medicine
Cancer Center Member
University of Vermont Medical Center*

September 25, 2022 – 8:45am ET

LOCATION: West Room, 1st Floor

VIRTUAL: <https://www.breakoutroom7.com>

The non-CME Ancillary Event titled:

Exploring Treatment Options in HER2+ Early Breast Cancer



PROVIDED BY: Genentech, Inc.

GUEST SPEAKER:

Dr. Robyn Young


*Clinical Director of Breast Cancer
The Center for Cancer and Blood Disorders
Fort Worth, TX*

4th Annual BREAST CANCER SYMPOSIUM

OPENING DOORS: Lab to Clinic to Patient

Notes

[illegible]



4th Annual **BREAST CANCER SYMPOSIUM**

OPENING DOORS: Lab to Clinic to Patient

Thank you to our Sponsors and Exhibitors:

GOLD SPONSORSHIP:

Pfizer Inc.

SILVER SPONSORSHIP:

Caris Life Sciences
Gilead Sciences, Inc
Novartis
Puma Biotechnology

BRONZE SPONSORSHIP:

Adaptive Biotechnologies
Agendia, Inc
BeiGene
Breast Cancer Index, BioTheranostics, Inc.
Daiichi Sankyo, Inc.
GE HealthCare
Genentech, Inc.
Incyte Corporation
Lilly USA, LLC
Merck & Co, Inc
NeoGenomics
Sanofi
Seagen, Inc.

PROUDLY HOSTED BY



World class cancer care. Close to home.

ACTIVITY PLANNED BY

